Nurses are on the frontlines of cancer care. Every day, they leverage their hands-on patient experience, resourcefulness and innovative mindsets to care for patients, carry out clinical trials, develop new models of healthcare delivery and advance evidence-based research. We believe nurses are uniquely positioned to identify best practices and opportunities for improvement in cancer prevention, treatment and remission care.
That’s why Johnson & Johnson is proud to announce the Johnson & Johnson Nurses Innovate QuickFire Challenge in Oncology, together with the Oncology Nursing Society (ONS). Nurses around the world are invited to submit their innovative ideas aimed at improving oncology care – including but not limited to prevention, early detection, treatment and care for cancer survivors.
“Oncology nurses spend a lot of time with patients with cancer and their families, and thus have extensive first-hand knowledge of the challenges and barriers in the cancer care delivery environment,” said Brenda Nevidjon, MSN, RN, FAAN, Chief Executive Officer at the Oncology Nursing Society. “Today, the oncology space is constantly experiencing changes and evolutions in diagnosis and treatment. This change, and sometimes chaos, can spur creativity and innovation, and we’re excited to invite the 36,000 members of the Oncology Nursing Society as well as nurses from around the world to submit their innovative ideas that have the power to improve cancer care and health outcomes for patients.”
Between 2011 and 2016, U.S. spending on cancer treatments almost doubled from about $26.8 billion to $42.1 billion.[1] In 2018, there were an estimated 17 million cases of cancer diagnosed around the world[2] and today, cancer accounts for about 1 in every 6 deaths worldwide – more than HIV/AIDS, tuberculosis and malaria combined.[3] Johnson & Johnson firmly believes nurses are our critical partners in the prevention and treatment of cancer, and that by working together, we can empower and elevate the next great idea with the potential to improve patient outcomes and strengthen health systems.
The Johnson & Johnson Nurses Innovate QuickFire Challenge series aims to expand the definition of what innovation means for frontline health workers by inviting nurses worldwide to develop and share their novel concepts, protocols, treatment approaches and device ideas that may have the power to profoundly change human health. The nurse innovators with the best idea(s) will receive up to $100,000 in grant funding and access to mentoring and coaching from experts across the Johnson & Johnson Family of Companies to help bring their ideas to life.
Applications will be evaluated by a diverse panel of subject matter experts on the uniqueness and feasibility of the idea, the thoroughness of the approach, the identification of key resources and plan to further the idea, and the idea’s potential to profoundly change human health outcomes. Applications must be submitted by practicing or retired nurses. The deadline to apply for the Johnson & Johnson Nurses Innovate QuickFire Challenge in Oncology is February 7, 2020 at midnight PST.
To learn more about the Johnson & Johnson Nurses Innovate QuickFire Challenge series, view previous awardees, and apply, visit nursing.jnj.com.
The Johnson & Johnson Nurses Innovate QuickFire Challenge series is part of the QuickFire Challenge platform which was developed by Johnson & Johnson Innovation - JLABS to attract and develop game-changing, early-stage innovation across the global therapeutics, consumer, health technologies, and medical devices sectors.
[1] Hong, S. J., Li, E. C., Matusiak, L. M., & Schumock, G. T. (2018). Spending on Antineoplastic Agents in the United States, 2011 to 2016. Journal of Oncology Practice, 14(11). doi: 10.1200/jop.18.00069
[2] Ferlay J. GLOBOCAN 2018. Lyon: World Health Organization International Agency for Research on Cancer, 2018.
[3] G. B. D. Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390: 1151-1210.
